Levomefolate calciumArtificial form of folate CAS# 151533-22-1 |
- Leucovorin Calcium
Catalog No.:BCC1198
CAS No.:6035-45-6
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 151533-22-1 | SDF | Download SDF |
| PubChem ID | 135564391 | Appearance | Powder |
| Formula | C20H23CaN7O6 | M.Wt | 497.5 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | H2O : 4.4 mg/mL (8.84 mM; Need ultrasonic and warming) | ||
| Chemical Name | calcium;(2S)-2-[[4-[[(6S)-2-amino-5-methyl-4-oxo-3,6,7,8-tetrahydropteridin-6-yl]methylamino]benzoyl]amino]pentanedioate | ||
| SMILES | CN1C(CNC2=C1C(=O)NC(=N2)N)CNC3=CC=C(C=C3)C(=O)NC(CCC(=O)[O-])C(=O)[O-].[Ca+2] | ||
| Standard InChIKey | VWBBRFHSPXRJQD-QNTKWALQSA-L | ||
| Standard InChI | InChI=1S/C20H25N7O6.Ca/c1-27-12(9-23-16-15(27)18(31)26-20(21)25-16)8-22-11-4-2-10(3-5-11)17(30)24-13(19(32)33)6-7-14(28)29;/h2-5,12-13,22H,6-9H2,1H3,(H,24,30)(H,28,29)(H,32,33)(H4,21,23,25,26,31);/q;+2/p-2/t12-,13-;/m0./s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Levomefolate is an artificial form of folate.
IC50 Value:
Target: Antifolate
The calcium salt of L-5-methyltetrahydrofolic acid which belongs to the group of folate vitamins (Vitamin B9, Folacin). It is a coenzymated form of folic acid and a more bioavailable alternative in dietary supplements. References: | |||||
Levomefolate calcium Dilution Calculator
Levomefolate calcium Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.0101 mL | 10.0503 mL | 20.1005 mL | 40.201 mL | 50.2513 mL |
| 5 mM | 0.402 mL | 2.0101 mL | 4.0201 mL | 8.0402 mL | 10.0503 mL |
| 10 mM | 0.201 mL | 1.005 mL | 2.0101 mL | 4.0201 mL | 5.0251 mL |
| 50 mM | 0.0402 mL | 0.201 mL | 0.402 mL | 0.804 mL | 1.005 mL |
| 100 mM | 0.0201 mL | 0.1005 mL | 0.201 mL | 0.402 mL | 0.5025 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
The calcium salt of L-5-methyltetrahydrofolic acid which belongs to the group of folate vitamins (Vitamin B9, Folacin). It is a coenzymated form of folic acid and a more bioavailable alternative in dietary supplements.
- N-[[1-[(2-Nitrophenyl)sulfonyl]-1H-indole-3-yl]methyl]-N-[1-[1-[(2-nitrophenyl)sulfonyl]-1H-indole-3-yl]-2-oxo-2-(tert-butylamino)ethyl]-1-(2-diazo-3-oxobutyryl)-2-oxo-3-methylpiperidine-3beta-carboxamide
Catalog No.:BCC8335
CAS No.:151513-70-1
- Ampelopsin F
Catalog No.:BCN3305
CAS No.:151487-08-0
- Swietemahalactone
Catalog No.:BCN6886
CAS No.:1514669-21-6
- Estradiol hexahydrobenzoate
Catalog No.:BCC8962
CAS No.:15140-27-9
- Pseudolarolide B
Catalog No.:BCN8093
CAS No.:151368-43-3
- Ro 32-0432 hydrochloride
Catalog No.:BCC7122
CAS No.:151342-35-7
- 3-O-p-Coumaroyloleanolic acid
Catalog No.:BCN3952
CAS No.:151334-06-4
- Zaleplon
Catalog No.:BCC5197
CAS No.:151319-34-5
- Inokosterone
Catalog No.:BCN3431
CAS No.:15130-85-5
- Genkwanol C
Catalog No.:BCN8012
CAS No.:151283-11-3
- CP 135807
Catalog No.:BCC7774
CAS No.:151272-90-1
- Primin
Catalog No.:BCN2729
CAS No.:15121-94-5
- RU 58668
Catalog No.:BCC7608
CAS No.:151555-47-4
- ent-3-Oxokauran-17-oic acid
Catalog No.:BCN1674
CAS No.:151561-88-5
- JJKK 048
Catalog No.:BCC5610
CAS No.:1515855-97-6
- XEN445
Catalog No.:BCC5382
CAS No.:1515856-92-4
- 6-Prenylquercetin-3-methylether
Catalog No.:BCN7992
CAS No.:151649-34-2
- H-D-Ser-OBzl.HCl
Catalog No.:BCC3097
CAS No.:151651-44-4
- SEP-0372814
Catalog No.:BCC6429
CAS No.:1516895-53-6
- 5-Deoxystrigol
Catalog No.:BCN7693
CAS No.:151716-18-6
- 2,2-Dimethyl-8-prenylchromene 6-carboxylic acid
Catalog No.:BCN1675
CAS No.:151731-50-9
- 4,4'-Dihydroxy-2,6-dimethoxydihydrochalcone
Catalog No.:BCN3583
CAS No.:151752-08-8
- Montelukast Sodium
Catalog No.:BCC4680
CAS No.:151767-02-1
- AC 187
Catalog No.:BCC6018
CAS No.:151804-77-2
The combined oral contraceptive pill containing drospirenone and ethinyl estradiol plus levomefolate calcium.[Pubmed:21877996]
Expert Opin Pharmacother. 2011 Oct;12(15):2403-10.
INTRODUCTION: Neural tube defects are the second most common congenital anomaly in the United States, although their incidence may be decreased by periconception folic acid supplementation. A new oral contraceptive containing drospirenone and ethinyl estradiol plus Levomefolate calcium was formulated to decrease the risk of neural tube defects in pregnancies conceived while taking or shortly after discontinuing this pill. AREAS COVERED: Because of its novelty, very few studies have been performed to evaluate the efficacy, side effects and safety related to contraception, premenstrual dysphoric disorder and acne; therefore, literature evaluating similar contraceptives without levomefolate is reviewed. Additionally, we review studies evaluating the addition of Levomefolate calcium to oral contraceptives containing 3 mg drospirenone and either 20 or 30 mug ethinyl estradiol. To date, no study has been performed to evaluate the effect this new oral contraceptive has on reducing the incidence of neural tube defects. EXPERT OPINION: This new pill has similar contraceptive efficacy, side effect, safety and benefits profile to other drospirenone-containing contraceptives. While also approved to prevent neural tube defects, no studies validate this claim and physician time is better spent counseling women, regardless of contraceptive choice, on the importance of folic acid supplementation during the child-bearing years.
Bioequivalence study of an oral contraceptive containing ethinylestradiol/drospirenone/levomefolate calcium relative to ethinylestradiol/drospirenone and to levomefolate calcium alone.[Pubmed:22067789]
Contraception. 2012 Feb;85(2):177-84.
BACKGROUND: A new tablet formulation containing 0.02 mg ethinylestradiol/3 mg drospirenone/0.451 mg Levomefolate calcium (calcium salt containing 0.416 mg L-5-methyltetrahydrofolate) was assessed for bioequivalence compared to the approved oral contraceptive (OC) tablet containing identical amounts of ethinylestradiol and drospirenone and to a tablet containing 0.451 mg Levomefolate calcium. STUDY DESIGN: Forty-four subjects received in an intraindividual crossover design single doses of the new tablet formulation or the established ethinylestradiol/drospirenone tablet or the Levomefolate calcium tablet. RESULTS: Bioequivalence was demonstrated for ethinylestradiol, drospirenone and L-5-methyltetrahydrofolate (active moiety of Levomefolate calcium) between the investigated tablet formulations. The geometric mean ratios of the AUC((0-tlast)) and C(max) values for all three compounds and their 90% confidence intervals were well within the 80%-125% range generally accepted to demonstrate bioequivalence. CONCLUSION: The rate and extent of absorption of ethinylestradiol and drospirenone were not affected by the concomitant administration of Levomefolate calcium and vice versa.
Bioequivalence evaluation of a folate-supplemented oral contraceptive containing ethinylestradiol/drospirenone/levomefolate calcium versus ethinylestradiol/drospirenone and levomefolate calcium alone.[Pubmed:22909145]
Clin Drug Investig. 2012 Oct 1;32(10):673-84.
BACKGROUND: Neural tube defects (NTDs) are congenital malformations that occur during early embryonic development. Suboptimal maternal folate status is a well-known risk factor for the occurrence of NTDs, and periconceptional folic acid supplementation has been shown to reduce the risk of NTDs. Folate-supplemented oral contraceptives (OCs) offer a means of improving folate status in women of childbearing potential by increasing their likelihood of having raised folate levels at the time of conception. OBJECTIVE: This study aimed to demonstrate bioequivalence of ethinylestradiol (EE), drospirenone and L-5-methyl-tetrahydrofolate (L-5-methyl-THF; active moiety of Levomefolate calcium) when taken as a new folate-supplemented OC containing EE/drospirenone/Levomefolate calcium, with the respective OC containing EE/drospirenone and a tablet containing Levomefolate calcium only. METHODS: This was a randomized, open-label, three-period crossover study carried out at a single centre in Germany. The study included 45 healthy women (age range 18-38 years). The women were randomly assigned to single doses of (i) EE 0.03 mg/drospirenone 3 mg/Levomefolate calcium 0.451 mg (SAFYRAL(R)), (ii) EE 0.03 mg/drospirenone 3 mg (Yasmin(R)), and (iii) Levomefolate calcium 0.451 mg, administered using a crossover design, with one or more menstrual cycle washout between doses. The primary variables were maximum concentrations (C(max)) and area under the concentration versus time curve (AUC) values for EE, drospirenone and L-5-methyl-THF. RESULTS: The bioavailability of EE and drospirenone was similar after administration of EE/drospirenone/Levomefolate calcium and EE/drospirenone. The geometric mean ratios (GMRs) and its 90% confidence intervals (CIs) for AUC values and C(max) were within the pre-specified range (80.00-125.00%) for bioequivalence for EE and drospirenone in both formulations. The bioavailability of L-5-methyl-THF was similar after administration of EE/drospirenone/Levomefolate calcium and Levomefolate calcium. The respective GMRs and 90% CIs of baseline-uncorrected and -corrected AUC(last) (AUC from time zero to time of last measurable concentration) and C(max) were also within the 80.00-125.00% range. CONCLUSION: The novel folate-supplemented OC EE/drospirenone/Levomefolate calcium is bioequivalent to the established OC Yasmin(R) (EE/drospirenone components) and to Levomefolate calcium (folate component).
EE-drospirenone-levomefolate calcium versus EE-drospirenone + folic acid: folate status during 24 weeks of treatment and over 20 weeks following treatment cessation.[Pubmed:23610531]
Int J Womens Health. 2013 Apr 11;5:149-63.
BACKGROUND: Adequate folate supplementation in the periconceptional phase is recommended to reduce the risk of neural tube defects. Oral contraceptives may provide a reasonable delivery vehicle for folate supplementation before conception in women of childbearing potential. This study aimed to demonstrate that a fixed-dose combination of an oral contraceptive and Levomefolate calcium leads to sustainable improvements in folate status compared with an oral contraceptive + folic acid. METHODS: This was a double-blind, randomized, parallel-group study in which 172 healthy women aged 18-40 years received ethinylestradiol (EE)-drospirenone-Levomefolate calcium or EE-drospirenone + folic acid for 24 weeks (invasion phase), and EE-drospirenone for an additional 20 weeks (folate elimination phase). The main objective of the invasion phase was to examine the area under the folate concentration time-curve for plasma and red blood cell (RBC) folate, while the main objective of the elimination phase was to determine the duration of time for which RBC folate concentration remained >/= 906 nmol/L after cessation of EE-drospirenone-Levomefolate calcium. RESULTS: Mean concentration-time curves for plasma folate, RBC folate, and homocysteine were comparable between treatment groups during both study phases. During the invasion phase, plasma and RBC folate concentrations increased and approached steady-state after about 8 weeks (plasma) or 24 weeks (RBC). After cessation of treatment with Levomefolate calcium, folate concentrations decreased slowly. The median time to RBC folate concentrations falling below 906 nmol/L was 10 weeks (95% confidence interval 8-12 weeks) after cessation of EE-drospirenone-Levomefolate calcium treatment. Plasma and RBC folate levels remained above baseline values in 41.3% and 89.3% of women, respectively, at the end of the 20-week elimination phase. CONCLUSION: Improvements in folate status were comparable between EE-drospirenone-Levomefolate calcium and EE-drospirenone + folic acid. Plasma and RBC folate levels remained elevated for several months following cessation of treatment with EE-drospirenone-Levomefolate calcium.
